Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA may be treated with either biological DMARDs (bDMARDs) or JAK inhibitors after inefficacy or intolerance of conventional DMARDs. To date, only few data are available on the persistence of the … Continue reading Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry